EQUITY RESEARCH MEMO

Nemera

Generated 5/10/2026

Executive Summary

Conviction (model self-assessment)60/100

Nemera is a France-based global leader in drug delivery device solutions, partnering with pharmaceutical, biotechnology, and generic companies to develop and manufacture safe, patient-centric treatments. Founded in 1999 and headquartered in La Verpillière, the company offers comprehensive services from design through lifecycle management, aiming to maximize treatment efficacy. With a focus on innovation and quality, Nemera supports customers across the entire device strategy and development lifecycle. As a private company with 201-500 employees, it has established itself as a key player in the drug delivery space, though its financial details and pipeline are not publicly disclosed.

Upcoming Catalysts (preview)

  • Q3 2026New Strategic Partnership with Top 20 Pharma70% success
  • TBDLaunch of Next-Generation Wearable Injector Platform50% success
  • Q4 2026Expansion into Biologics and Large-Molecule Delivery60% success
Locked sections
  • · Pipeline Analysis
  • · Competitive Landscape
  • · Catalyst Calendar (full 12-month)
  • · Bull Case
  • · Bear Case
  • · Counterfactual Scenarios
  • · Valuation Notes
  • · SEC Filing Highlights
  • · Insider Activity
  • · Literature Watch
  • · Patent Landscape
  • · Mechanism Cluster Map
  • · Audio Briefing (5 min)